GlassScriptPhysician profile
Renuka D Patel
NPI 1467447904
$1,472.81
in general payments reported to CMS, 2019-2025
22 companies · $71.50 in 2025
The $71.50 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.43 · 2020: $96.98 · 2021: $284 · 2022: $312 · 2023: $407 · 2024: $259 · 2025: $71.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $179.47 | 2022-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $123.48 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $120.94 | 2021 | |
| Novo Nordisk INC | $112.09 | 2024-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $99.76 | 2022-2024 | Jardiance, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.92 | 2021-2024 | Jardiance |
| Pfizer INC. | $91.06 | 2020-2023 | |
| Merz North America, INC. | $90.18 | 2023 | Xeomin |
| Astrazeneca Pharmaceuticals LP | $76.72 | 2024 | Farxiga, Airsupra |
| Abbott Laboratories | $70.00 | 2022-2023 | Freestyle Libre 2 |
| Allergan, INC. | $57.60 | 2020 | |
| Abbvie INC. | $55.98 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.08 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $42.43 | 2019 | |
| Sanofi Pasteur INC. | $40.02 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $37.28 | 2021 | |
| Paratek Pharmaceuticals, INC. | $30.96 | 2021-2023 | Nuzyra |
| Amgen INC. | $26.12 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.71 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.59 | 2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $14.28 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.14 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renuka Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.